Publications by authors named "Justine Seivright"
Ustekinumab in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis.
Dermatol Ther (Heidelb)
July 2024
Article Synopsis
- Hidradenitis suppurativa (HS) is a painful skin condition with limited treatment options; adalimumab is the only FDA-approved biologic, prompting interest in ustekinumab as an alternative therapy.
- A systematic review and meta-analysis were conducted on 10 studies involving 88 patients, revealing that ustekinumab had a pooled response rate of 67%, particularly in patients with more severe disease who had previously failed other treatments.
- The study suggests that ustekinumab could be a viable option for HS patients who do not respond to standard biologic treatments, although more randomized controlled trials are needed to establish effective dosing and identify which patients might benefit most.
Geographic maldistribution of dermatologists contributes to disparities in access to dermatologic care. We aimed to investigate the geographic distribution of, and differences in wait times for medical dermatology services in Los Angeles County (LAC). We placed phone calls to 251 dermatology practices in LAC to ask for a new patient appointment for a changing mole.
View Article and Find Full Text PDFIntroduction: Hidradenitis suppurativa (HS) can significantly impact patients' relationships.
Methods: Using an anonymous electronic survey, we aimed to determine what aspects of sexual relationships are affected by HS discomfort and patients' reluctance to discuss HS with their partner.
Results: Among the 873 participants, 60.
Atopic dermatitis (AD) affects up to 20% of children worldwide. We identified the top 50 cited AD articles in the last seven decades and examined their characteristics. The majority were discussing the pathogenesis of AD and have paved the way for discovering targeted immunomodulatory treatments.
View Article and Find Full Text PDFIntroduction: Pediatric hidradenitis suppurativa (HS) is an understudied condition, and the literature describing the provider landscape for this disease is limited. We aim to characterize healthcare utilization in a cohort of pediatric HS patients at an academic institution.
Methods: Patients diagnosed with HS before age 18 were identified via retrospective chart review using ICD-9/10 codes for HS.
Article Synopsis
- Hidradenitis suppurativa (HS) is gaining global attention, yet research is predominantly originating from North America and Europe, prompting a bibliometric analysis focused on Asia and Australasia over the past decade.
- The analysis revealed 163 HS-related articles from the region, with a significant publication spike after 2015, predominantly consisting of case reports, while efforts were made to produce more high-level evidence studies.
- Major contributors to HS research included China, Japan, and India, with an increasing involvement from Australia, Israel, and Turkey, highlighting the need for greater geographical representation in research to enhance understanding and treatment of the disease.
Article Synopsis
- Biologic medications are being explored as local treatments for inflammatory skin conditions, focusing on intralesional (IL) administration where results are less common compared to systemic use.
- A systematic review of studies from 2000 to 2020 showed that intralesional biologics effectively treated conditions like pemphigus vulgaris and granuloma faciale, but results for conditions like sarcoidosis were inconsistent.
- While local biologic treatments could be beneficial, more research is necessary to standardize dosages, clarify effectiveness, and determine the best types of patients for these therapies.
Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients.
View Article and Find Full Text PDFArticle Synopsis
- * A study identified 29 HSSCs across 16 states, which is an increase since 2019, but many regions, especially the Mountain West and East South Central areas, still lack access to these clinics.
- * Most HSSC directors are dermatologists with recent residency experience, involved heavily in research, and over half of the clinics participate in HS clinical trials, highlighting the importance of expanding these clinics for better patient care.
Background: Hormones are thought to play a role in hidradenitis suppurativa (HS). However, data on the HS disease course during pregnancy and the postpartum period has not been well established. The objective of this study is to analyze the available literature to determine HS disease activity during pregnancy and the postpartum period.
View Article and Find Full Text PDFBackground/objectives: Hidradenitis suppurativa (HS) is understudied in the pediatric population. Adult HS patients are known to have a high comorbidity burden. We aimed to describe physical and psychosocial comorbidities in a cohort of pediatric HS patients.
View Article and Find Full Text PDFBackground: Hidradenitis suppurativa (HS) has historically been a neglected disease. However, research in this field has grown exponentially in the past decade.
Methods: The top-cited HS articles from 1950 to 2020 were analyzed for authorship, study topic, study design, and senior author country of origin.
Article Synopsis
- * A systematic review analyzed the effectiveness, patient demographics, and side effects of using low-dose radiotherapy for HS, revealing it as a potential option for treatment-resistant cases.
- * Despite some positive outcomes, there's still a lack of agreement on the best practices for using radiotherapy in HS, including how to choose patients and dosage recommendations.
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that disproportionately affects women of childbearing age. Pregnancy influences HS severity for many women, thus diligent continued management throughout pregnancy and postpartum may be required. Herein, we provide an updated review of pregnancy and lactation safety data for HS medications, including topical antiseptic washes, topical and systemic antibiotics, biologic and nonbiologic immunomodulators, immunosuppressants, adjunct medical therapies, and pain medications, to help guide risk-benefit discussions between providers and HS patients.
View Article and Find Full Text PDF